This One Data Readout Will Make Or Break Sellas Life Sciences Group (NASDAQ:SLS)
· seekingalpha.com
SELLAS Life Sciences Group is a high-conviction buy ahead of the pivotal Phase 3 REGAL trial readout for GPS in AML. Click here to read this SLS stock update.
My buy-call on SELLAS Life Science Group, Inc. ( SLS ) here would ultimately come down to the debate surrounding what we’re seeing drive the unusually long RE...